369 related articles for article (PubMed ID: 17459021)
21. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients.
Lutgens LC; Deutz N; Granzier-Peeters M; Beets-Tan R; De Ruysscher D; Gueulette J; Cleutjens J; Berger M; Wouters B; von Meyenfeldt M; Lambin P
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):275-85. PubMed ID: 15337566
[TBL] [Abstract][Full Text] [Related]
22. Clinically active Crohn's disease in the presence of a low C-reactive protein.
Florin TH; Paterson EW; Fowler EV; Radford-Smith GL
Scand J Gastroenterol; 2006 Mar; 41(3):306-11. PubMed ID: 16497618
[TBL] [Abstract][Full Text] [Related]
23. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: a randomized cross-over study.
Bours MJ; Bos HJ; Meddings JB; Brummer RJ; van den Brandt PA; Dagnelie PC
BMC Gastroenterol; 2007 Jun; 7():23. PubMed ID: 17578566
[TBL] [Abstract][Full Text] [Related]
24. Intestinal sugar permeability: relationship to diarrhoeal disease and small bowel morphology.
Ford RP; Menzies IS; Phillips AD; Walker-Smith JA; Turner MW
J Pediatr Gastroenterol Nutr; 1985 Aug; 4(4):568-74. PubMed ID: 4032170
[TBL] [Abstract][Full Text] [Related]
25. Correlations of plasma citrulline levels with clinical and endoscopic score and blood markers according to small bowel involvement in pediatric Crohn disease.
Lee EH; Ko JS; Seo JK
J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):570-5. PubMed ID: 23752073
[TBL] [Abstract][Full Text] [Related]
26. Local effect of adenosine 5'-triphosphate on indomethacin-induced permeability changes in the human small intestine.
Bours MJ; Troost FJ; Brummer RJ; Bast A; Dagnelie PC
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):245-50. PubMed ID: 17301652
[TBL] [Abstract][Full Text] [Related]
27. Differential sugar absorption as a marker for adaptation in short bowel syndrome.
Sigalet DL; Martin GR; Poole A
J Pediatr Surg; 2000 May; 35(5):661-4. PubMed ID: 10813318
[TBL] [Abstract][Full Text] [Related]
28. [Mean platelet volume (MPV) in Crohn's disease patients].
Douda T; Bures J; Rejchrt S; Kopácová M; Pecka M; Malý J
Cas Lek Cesk; 2006; 145(11):870-3. PubMed ID: 17168422
[TBL] [Abstract][Full Text] [Related]
29. Intestinal permeability test as a predictor of clinical course in Crohn's disease.
D'Incà R; Di Leo V; Corrao G; Martines D; D'Odorico A; Mestriner C; Venturi C; Longo G; Sturniolo GC
Am J Gastroenterol; 1999 Oct; 94(10):2956-60. PubMed ID: 10520851
[TBL] [Abstract][Full Text] [Related]
30. The citrulline generation test: proposal for a new enterocyte function test.
Peters JH; Wierdsma NJ; Teerlink T; van Leeuwen PA; Mulder CJ; van Bodegraven AA
Aliment Pharmacol Ther; 2008 Jun; 27(12):1300-10. PubMed ID: 18331613
[TBL] [Abstract][Full Text] [Related]
31. [Clinical features of Crohn's disease: relationship of disease type and severity to clinical findings at the time of diagnosis in 166 cases].
Tominaga M
Fukuoka Igaku Zasshi; 1992 Jan; 83(1):6-20. PubMed ID: 1547990
[TBL] [Abstract][Full Text] [Related]
32. Increased leukocyte adhesiveness/aggregation is the single best biochemical indicator of disease activity in adolescent patients with inflammatory bowel disease.
Arber N; Berliner S; Reif S; Dotan I; Liberman E; Aschkenasy M; Vila Y; Gilat T; Bujanover Y
J Med; 1996; 27(5-6):319-31. PubMed ID: 9151200
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal cytokine productions and their relationship to peritoneal sepsis and systemic inflammatory markers in patients with inflammatory bowel disease.
Yamamoto T; Umegae S; Kitagawa T; Matsumoto K
Dis Colon Rectum; 2005 May; 48(5):1005-15. PubMed ID: 15785898
[TBL] [Abstract][Full Text] [Related]
34. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans.
Crenn P; Coudray-Lucas C; Thuillier F; Cynober L; Messing B
Gastroenterology; 2000 Dec; 119(6):1496-505. PubMed ID: 11113071
[TBL] [Abstract][Full Text] [Related]
35. Faecal calprotectin in the assessment of Crohn's disease activity.
Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
[TBL] [Abstract][Full Text] [Related]
36. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
37. Are single measurements of pseudocholinesterase and albumin markers for inflammatory activity or nutritional status in Crohn's disease?
Novacek G; Vogelsang H; Schmidt B; Lochs H
Wien Klin Wochenschr; 1993; 105(4):111-5. PubMed ID: 8451851
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of C-reactive protein with activity of Crohn's disease].
Yang CH; Chen XY; Yang F; Ran ZH; Liu WZ; Xiao SD
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1253-5. PubMed ID: 16796884
[TBL] [Abstract][Full Text] [Related]
39. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
[TBL] [Abstract][Full Text] [Related]
40. Plasma lipids and inflammation in active inflammatory bowel diseases.
Romanato G; Scarpa M; Angriman I; Faggian D; Ruffolo C; Marin R; Zambon S; Basato S; Zanoni S; Filosa T; Pilon F; Manzato E
Aliment Pharmacol Ther; 2009 Feb; 29(3):298-307. PubMed ID: 19035968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
